Analysts expect that Neptune Wellness Solutions Inc (NASDAQ:NEPT) (TSE:NTB) will post $10.99 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Neptune Wellness Solutions’ earnings, with the lowest sales estimate coming in at $10.79 million and the highest estimate coming in at $11.36 million. Neptune Wellness Solutions reported sales of $21.53 million in the same quarter last year, which would suggest a negative year over year growth rate of 49%. The company is scheduled to issue its next quarterly earnings results on Monday, November 15th.
According to Zacks, analysts expect that Neptune Wellness Solutions will report full-year sales of $51.13 million for the current year, with estimates ranging from $50.48 million to $51.92 million. For the next year, analysts anticipate that the firm will report sales of $94.72 million, with estimates ranging from $83.58 million to $105.86 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Neptune Wellness Solutions.
Neptune Wellness Solutions (NASDAQ:NEPT) (TSE:NTB) last posted its earnings results on Wednesday, August 11th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). The firm had revenue of $10.08 million for the quarter, compared to analyst estimates of $8.87 million. Neptune Wellness Solutions had a negative return on equity of 74.86% and a negative net margin of 344.98%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Credit Suisse AG acquired a new stake in shares of Neptune Wellness Solutions during the first quarter worth about $41,000. Resources Investment Advisors LLC. acquired a new stake in shares of Neptune Wellness Solutions during the first quarter worth about $79,000. Scotia Capital Inc. acquired a new stake in shares of Neptune Wellness Solutions during the second quarter worth about $70,000. Geode Capital Management LLC boosted its stake in shares of Neptune Wellness Solutions by 230.0% during the first quarter. Geode Capital Management LLC now owns 73,564 shares of the biotechnology company’s stock worth $96,000 after buying an additional 51,270 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Neptune Wellness Solutions by 981.0% during the second quarter. Goldman Sachs Group Inc. now owns 139,978 shares of the biotechnology company’s stock worth $164,000 after buying an additional 127,029 shares during the period. Institutional investors own 12.41% of the company’s stock.
NASDAQ:NEPT traded down $0.08 during trading hours on Monday, hitting $0.57. The company’s stock had a trading volume of 1,579,643 shares, compared to its average volume of 3,415,835. The stock has a market capitalization of $95.82 million, a P/E ratio of -0.56 and a beta of 2.42. The stock has a fifty day moving average of $0.72 and a 200-day moving average of $1.11. The company has a current ratio of 3.05, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Neptune Wellness Solutions has a 52-week low of $0.55 and a 52-week high of $3.60.
About Neptune Wellness Solutions
Neptune Wellness Solutions Inc, a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils.
Featured Story: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neptune Wellness Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Wellness Solutions and related companies with MarketBeat.com's FREE daily email newsletter.